<DOC>
	<DOCNO>NCT01214720</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability Avastin versus placebo add chemotherapeutic regimen patient metastatic pancreatic cancer . The anticipated time study treatment confirm evidence disease progression , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Added Chemotherapeutic Regimen Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; metastatic pancreatic cancer ( adenocarcinoma ) ; good liver , kidney , bone marrow function . previous systemic treatment metastatic pancreatic cancer ; pregnant lactating female ; fertile men , woman childbearing potential , use adequate contraception ; major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start ; current recent treatment ( within 30 day prior start study treatment ) another investigational drug , participation another investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>